Drug targeting by surface cationization

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 17, Issue 5, 2000, Pages 425-465

  Blau, Sigal ^a   Jubeh, Tareq Taha ^a   Haupt, Susan Moody ^a   Rubinstein, Abraham ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Cationic liposomes; Cationized antioxidants; Cationized emulsions; Cationized polymers; Gene delivery

Indexed keywords

1,2 DIMYRISTOYL 3 TRIMETHYLAMMONIUM PROPANE; 1,2 DIMYRISTYLOXYPROPYL 3 DIMETHYLHYDROXYETHYLAMMONIUM BROMIDE; 1,6 HEXANEDIAMINE; 2,3 DIOLEYLOXY N [2 (SPERMINECARBOXYANIDO)ETHYL] N,N DIMETHYL 1 PROPANAMINIUM TRIFLUOROACETATE; 3BETA [N (N',N' DIMETHYLAMINOETHANE)CARBAMOYL]CHOLESTEROL; ANTIOXIDANT; BACTERICIDE; CATION; CHITOSAN; DIAMINE; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; DIOCTADECYLAMIDOGLYCYLSPERMINE; DRUG; DRUG CARRIER; ETHYLENEDIAMINE; LIPOFECTIN; LIPOSOME; N (2 HYDROXYETHYL) N,N DIMETHYL 2,3 BIS(DODECYCLOXY) 1 PROPANAMINIUM BROMIDE; N,N DIMETHYL 1,3 PROPANEDIAMINE; NUCLEOTIDE; POLYAMINE; POLYARGININE; POLYHISTIDINE; POLYLYSINE; POLYMER; PROTEIN; PUTRESCINE; SPERMIDINE; SPERMINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL TRANSPORT; CLINICAL TRIAL; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG TARGETING; DRUG UPTAKE; EMULSION; ENDOCYTOSIS; ENDOSOME; GENE TARGETING; HUMAN; IMMUNOGENICITY; INTERNALIZATION; IONIZATION; MACROMOLECULE; NONHUMAN; REVIEW; SURFACE PROPERTY;

EID: 0033778347     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevtherdrugcarriersyst.v17.i5.10     Document Type: Review

References (202)

1. Chemical highlights of polyamine transport
2. Proteoglycan involvement in polyamine uptake
3. Antibiotic peptides and serine protease homologs in human polymorphonuclear leukocytes: Defensins and azurocidin
4. Defensins. Natural peptide antibiotics of human neutrophils
5. Antibiotic peptides as mediators of innate immunity
6. Defensins: Endogenous antibiotic peptides from human leukocytes
7. Direct cytotoxicity of polymorphonuclear leukocyte granule proteins to human lung-derived cells and endothelial cells
8. Cationic polyelectrolytes: A new look at their possible roles as opsonins, as stimulators of respiratory burst in leukocytes, in bacteriolysis, and as modulators of immune-complex diseases
9. Cell damage in inflammatory and infectious sites might involve a coordinated 'cross-talk' among oxidants, microbial haemolysins and ampiphiles, cationic proteins, phospholipases, fatty acids, proteinases, and cytokines
10. Molecular mechanisms of endocytosis
11. Diffusion of univalent ions across the lamellae of swollen phospholipids
12. Preparation and characterization of liposomes as therapeutic delivery systems: A review
13. Drug delivery systems. 1. Site-specific drug delivery using liposomes as carriers
14. Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure
15. Cationic lipid-based gene delivery systems: Pharmaceutical perspectives
16. Synthesis, activity, and structure - Activity relationship studies of novel cationic lipids for DNA transfer
17. A novel cationic liposome reagent for efficient transfection of mammalian cells
18. Cholesterol enhances cationic liposome-mediated DNA transfection of human respiratory epithelial cells - Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA
19. Cholesterol enhances cationic liposome-mediated DNA transfection of human respiratory epithelial cells
20. Endocytosis and intracellular processing accompanying transfection mediated by cationic liposomes
21. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations
22. Electrostatic and structural properties of complexes involving plasmid DNA and cationic lipids commonly used for gene delivery
23. Physicochemical and morphological properties of complexes made of cationic liposomes and oligonucleotides
24. Interactions of mammalian cells with lipid dispersions containing novel metabolizable cationic amphiphiles
25. Characterization of cationic liposome-mediated gene transfer in vivo by intravenous administration
26. Cationic liposome-mediated gene transfer
27. Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung
28. LipofectAMINE reagent: A new, higher efficiency polycationic liosome reagent
29. Cationic liposome-mediated gene transfer
30. Structural requirements for cationic lipid mediated phosphorothioate oligonucleotides delivery to cells in culture
31. Cationic liposome-mediated transfection
32. In vivo transfection of murine lungs with a functioning prokaryotic gene using a liposome vehicle
33. Improved cationic lipid formulations for in vivo gene therapy
34. Converting an alcohol to an amine in a cationic lipid dramatically alters the co-lipid requirement, cellular transfection activity and the ultrastructure of DNA-cytofectin complexes
35. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery
36. Positively charged submicron emulsions - A new type of colloidal drug carrier
37. The design and characterization of a positively charged submicron emulsion containing a sunscreen agent
38. Physicochemical characterization and acute toxicity evaluation of a positively-charged submicron emulsion vehicle
39. Prevention of topical and ocular oxidative stress by positively charged submicron emulsion
40. Positively and negatively charged submicron emulsions for enhanced topical delivery of antifungal drugs
41. Evaluation of a positively charged submicron emulsion of piroxicam on the rabbit corneum healing process following alkali burn
42. Chitosan and its use as a pharmaceutical excipient
43. Formulation and biological activity of antineoplastic proteoglycans derived from Mycobacterium vaccae in chitosan nanoparticles
44. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers
45. Preparation of a prolonged release tablet of aspirin with chitosan
46. Investigation of prolonged drug release from matrix formulations of chitosan
47. Sustained release of indomethacin from chitosan granules
48. Chitosan as a novel nasal delivery system for peptide drugs
49. Enhancement of nasal absorption of insulin using chitosan nanoparticles
50. Effect of interpolymer complex formation on bioadhesive property and drug release phenomenon of compressed tablet consisting of chitosan and sodium hyaluronate
51. Chitosan and sodium alginate based bioadhesive tablets for intraoral drug delivery
52. The effect of chronic nasal application of chitosan solution on cilia beat frequency in guinea pigs
53. Toxicity of chitosan
54. Arterial uptake of biodegradable nanoparticles: Effect of surface modifications
55. Microencapsulation of erythrocytes in Eudragit-RL-coated calcium alginate
56. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier
57. A method for the quantitative modification and estimation of carboxylic acid groups in proteins
58. Use of cationized ferritin as a label of negative charges on cell surfaces
59. Induction of membranous nephropathy in rabbits by administration of an exogenous cationic antigen
60. Enhanced permeabilities of cationized bovine serum albumins at the blood-nerve and blood-brain barriers in awake rats
61. Treatment of human immunodeficiency virus-infected lymphocytes with cationized human immunoglobulins
62. Pathogenicity of cationized albumin in the dog: Renal and extrarenal effects
63. The role of cationized catalase and cationized glucose oxidase in mucosal oxidative damage induced in the rat jejunum
64. Isolation and characterization of normal and neoplastic colonic epithelial cell populations
65. Anionic sites in the glomerular basement membrane. In vivo and in vitro localization to the laminae rarae by cationic probes
66. Activation of human neutrophils and monocytes induced by immune complexes prepared with cationized antibodies or antigens
67. Cationization of bovine serum albumin alters its conformation as well as its charge
68. Protection of the rat jejunal mucosa against oxidative injury by cationized superoxide dismutase
69. The effect of adhesive antioxidant enzymes on experimental colitis in the rat
70. Brain delivery of biotin bound to a conjugate of neutral avidin and cationized human albumin
71. Characterization of pulmonary endothelial charge barrier
72. Enhanced endocytosis and antihuman immunodeficiency virus type 1 activity of anti-rev antibodies after cationization
73. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid
74. Studies on the reaction of fluorescamine with primary amines
75. Improvement of therapeutic effect of human recombinant superoxide dismutase on ischemic acute renal failure in the rat via cationization and conjugation with polyethylene glycol
76. Enhanced endocytosis in cultured human breast carcinoma cells and in vivo biodistribution in rats of a humanized monoclonal antibody after cationization of the protein
77. Cationization of a monoclonal antibody to the human immunodeficiency virus REV protein enhances cellular uptake but does not impair antigen binding of the antibody
78. Disposition of positively charged Bowman-Birk protease inhibitor conjugates in mice: Influence of protein conjugate charge density and size on lung targeting
79. In vivo fluorescence imaging of the transport of charged chlorin e6 conjugates in a rat orthotopic prostate tumour
80. Conjugation of poly-L-lysine to albumin and horseradish peroxidase: A novel method of enhansing the cellular uptake of proteins
81. Cationization of catalase, peroxidase, and superoxide dismutase. Effect of improved intraarticular retention on experimental arthritis in mice
82. Formation and use of poly-L-histidine-catalase complexes: Protection of cells from hydrogen peroxide-mediated injury
83. Gene therapy for cerebrovascular disease
84. Transfer of genes to humans: Early lessons and obstacles to success
85. Direct in vivo gene transfer into the coronary and peripheral vasculatures of the intact dog
86. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein
87. Mechanisms of DNA entry into mammalian cells. II. Phagocytosis of calcium phosphate DNA co-precipitate visualized by electron microscopy
88. High efficiency transformation by direct microinjection of DNA into cultured mammalian cells
89. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment
90. Polyamidoamine cascadepolymers mediate efficient transfection of cell in culture
91. In vitro cytotoxicity of poly(amidoamine)s: Relevance to DNA delivery
92. Nonviral gene therapy: The promise of genes as pharmaceutical products
93. Transferrin-polycation conjugates as carriers for DNA uptake into cells
94. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides
95. Cellular and molecular barriers to gene transfer by a cationic lipid. Cationic lipid-based gene delivery systems: Pharmaceutical perspectives
96. Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides
97. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer
98. Mechanism of oligonucleotide release from cationic liposomes
99. Cytoplasmic expression of a reporter gene by co-delivery of T7 RNA polymerase and T7 promoter sequence with cationic liposomes
100. Nuclear targeting sequences - A consensus?
101. Gene transfer with synthetic cationic amphiphiles: Prospects for gene therapy
102. Nuclear localization signal peptides enhance cationic liposome-mediated gene therapy
103. Characterization of nuclear factors for elicitor-mediated activation of the promoter of the pea phenylalanine ammonia-lyase gene 1
104. Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: Comparison with cationic liposomes
105. Uptake of charged liposomes by the rat liver
106. Intratracheal administration of interleukin 12 plasmid-cationic lipid complexes inhibits murine lung metastases
107. Aerosol and intravenous transfection of human alpha 1-antitrypsin gene to lungs of rabbits
108. Recombinant gene expression in vivo within endothelial cells of the arterial wall
109. Plasmid DNAs directly injected into mouse brain with lipofectin can be incorporated and expressed by brain cells. Mutagenicity of metal cations in cultured cells from Chinese hamster
110. Persistence of plasmid DNA and expression in rat brain cells in vivo
111. Immunotherapy of malignancy by in vivo gene transfer into tumors
112. Cationic lipids for reporter gene and CFTR transfer to rat pulmonary epithelium
113. Aerosol gene delivery in vivo
114. Noninvasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice
115. Expression of the human cystic fibrosis transmembrane conductance regulator gene in the mouse lung after in vivo intratracheal plasmid-mediated gene transfer
116. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans
117. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis
118. Transferrin-polycation-DNA complexes: The effect of polycations on the structure of the complex and DNA delivery to cells
119. Potentiation of cationic liposome-mediated gene delivery by polycations
120. Expression of naked plasmids by cultured myotubes and entry of plasmids into T tubules and caveolae of mammalian skeletal muscle
121. In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes
122. The interaction of positively charged phospholipid vesicles with bacteria
123. Lipoplexes and tumours. A review
124. Gene therapy approaches for inherited and acquired lung diseases
125. Report to the NIH Recombinant DNA Advisory Committee on murine replication-competent retrovirus (RCR) assays (February 17, 1993)
126. Current status of CF gene therapy
127. Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans
128. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection
129. Systemic gene expression after intravenous DNA delivery into adult mice
130. DC-Cholliposomes as DNA carriers for gene therapy
131. The effect of cationic liposome pretreatment and centrifugation on retrovirus-mediated gene transfer
132. Virosomes: Cationic liposomes enhance retroviral transduction
133. Cationic liposomes (Lipofectin) mediate retroviral infection in the absence of specific receptors
134. The interaction of phospholipid liposomes with bacteria and their use in the delivery of bactericides
135. Encapsulation of vancomycin and gentamicin within cationic liposomes for inhibition of growth of Staphylococcus epidermidis
136. Interactions between cationic liposomes and bacteria: The physical-chemistry of the bactericidal action
137. Cationiic vesicles as bactericides
138. Bacteria flocculation and death by cationic vesicles
139. Interaction between cationic vesicles and Escherichia coli
140. Liposomes are effective carriers for the ocular delivery of prophylactics
141. Liposomes and tear fluid, I. Release of vesicle-entrapped carboxyfluorescein
142. Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier
143. Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery
144. Receptor-mediated peptide transport through the blood-brain barrier
145. Permeability and mechanism of albumin, cationized albumin, and glycosylated albumin transcellular transport across monolayers of cultured bovine brain capillary endothelial cells
146. Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins
147. Surface charges associated with fenestrated brain capillaries. I. In vitro labeling of anionic sites
148. Effect of molecular charge on choroid-plexus permeability: Tracer studies with cationized ferritins
149. Regional blood-brain barrier transport of cationized bovine serum albumin in awake rats
150. Ultrastructural study on the interaction of native and cationized albumin-gold complexes with mouse brain microvascular endothelium
151. Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport
152. Absence of albumin receptor on brain capillaries in vivo or in vitro
153. Beta-endorphin chimeric peptides: Transport through the blood-brain barrier in vivo and cleavage of disulfide linkage by brain
154. Blood-brain barrier transport of cationized immunoglobulin G: Enhanced delivery compared to native protein
155. Transport of cationized anti-tetanus Fab '2 fragments across an in vitro blood-brain barrier model: Involvement of the transcytosis pathway
156. Facilitation of passive avoidance response by newly synthesized cationized arginine vasopressin fragment 4-9 in rats
157. Development and in vitro characterization of a cationized monoclonal antibody against beta A4 protein: A potential probe for Alzheimer's disease
158. Pilocarpine incorporated into a submicron emulsion vehicle causes an unexpectedly prolonged ocular hypotensive effect in rabbits
159. A submicron emulsion as ocular vehicle for delta-8-tetrahydrocannabinol: Effect on intraocular pressure in rabbits
160. Prevention of oxidative damage in fibroblast cell cultures and rat skin by positively-charged submicron emulsion of α-tocopherol
161. Interaction of a self-emulsifying lipid drug delivery system with the everted rat intestinal mucosa as a function of droplet size and surface charge
162. Positively charged self-emulsifying oil formulation for improving oral bioavailability of progesterone
163. Inflammation, free radicals, and antioxidants
164. Prevention and induction of oxidative damage in E. coli cells by cationized proteins
165. Enhanced cellular uptake and in vivo biodistribution of a monoclonal antibody following cationization
166. Cationization of protein antigens, I. Alteration of immunogenic properties
167. Ganglioside conjugate vaccines. Immunotherapy against tumors of neuroectodermal origin
168. Human immune response to cationized proteins, I. Characterization of the in vitro response to cationized diphtheria toxoid
169. Oral tolerance and accessory-cell function of Peyer's patches
170. Immunosuppression caused by antigen feeding, I. Evidence for the activation of a feedback suppressor pathway in the spleens of antigen-fed mice
171. Cationization of protein antigens, III. Abrogation of oral tolerance
172. Cationization of immunoglobulin G results in enhanced organ uptake of the protein after intravenous administration in rats and primate
173. Hepatic disposition characteristics of electrically charged macromolecules in rat in vivo and in the perfused liver
174. Cationized hyperimmune immunoglobulins: Pharmacokinetics, toxicity evaluation and treatment of human immunodeficiency virus-infected human-peripheral blood lymphocytes-severe combined immune deficiency mice
175. Hepatic disposition and toxicity of cationized goat immunoglobulin G and fab fragments in isolated perfused rat liver
176. Manipulation of renal disposition of human recombinant superoxide dismutase by chemical modification
177. Emulsions as drug carriers - Possibilities, limitations, and future perspectives
178. Toxicity of some charged lipids used in liposome preparations
179. Liposome toxicity in the mouse central nervous system
180. Cationization of protein antigens, VI. Effects of cationization on the immunoregulatory properties of a bovine serum albumin peptide, a. a. 506-589
181. Cationization of protein antigens, II. Alteration of regulatory properties
182. Cationization of protein antigens, IV. Increased antigen uptake by antigen-presenting cells
183. Cationization of protein antigens, V. Effect of the degree of cationization on patterns of immune responsiveness
184. Evaluation of cationized rat albumin as a potential blood-brain barrier drug transport vectors
185. Quantitative studies of in situ immune complex glomerulonephritis in the rat induced by planted, cationized antigen
186. Electrical charge of the antigen determines intraarticular antigen handling and chronicity of arthritis in mice
187. Allergic arthritis induced by cationic antigens: Relationship of chronicity with antigen retention and T-cell reactivity
188. An active model of immune complex glomerulonephritis in the rat employing cationized antigen
189. Anionic binding sites in the glomerular basement membrane: Possible role in the pathogenesis of immune complex glomerulonephritis
190. A model of in situ immune complex glomerulonephritis in the rat employing cationized ferritin
191. Interaction of cationized antigen with rat glomerular basement membrane: In situ immune complex formation
192. Charge of circulating immune complexes as a factor in glomerular basement membrane localization in mice
193. Nephritogenicity and differential distribution of glomerular immune complexes related to immunogen charge
194. Effects of synthetic polycations on leucine incorporation, lactate dehydrogenase release, and morphology of human umbilical vein endothelial cells
195. Ototoxicity in vitro: Effects of neomycin, gentamicin, dihydrostreptomycin, amikacin, spectinomycin, neamine, spermine and poly-L-lysine
196. In vitro cytotoxicity of poly(amidoamine)s: Relevance to DNA delivery
197. Antineoplastic activity of poly(L-lysine) with some ascites tumor cells
198. Biochemical characterisation of polycation-induced cytotoxicity to human vascular endothelial cells
199. Effect of polycations on the function of the isolated perfused rat kidney
200. Altering the blood-brain barrier in the rat by intracarotid infusion of polycations: A comparison between protamine, poly-L-lysine and poly-L-arginine
201. In vitro myotoxicity of selected cationic macromolecules used in nonviral gene delivery